Policy Developments - The National Health Commission released the "Guidelines for the Construction and Management of Geriatric Medicine Departments (2025 Edition)", requiring that secondary and higher-level hospitals establish geriatric medicine departments with specific standards for bed allocation and service models [2] Drug and Device Approvals - Roche announced that its innovative bispecific antibody Glofitamab has received approval from the National Medical Products Administration for a new indication to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma [4] - Heng Rui Pharma's application for the CDK4/6 inhibitor Darsylis has been accepted by the National Medical Products Administration for use in early or locally advanced breast cancer [5] - Boehringer Ingelheim's drug Niramolast is proposed for priority review for the treatment of progressive pulmonary fibrosis, showcasing its dual anti-fibrotic and anti-inflammatory effects [6] Financial Data - Zai Lab reported a total revenue of $106.5 million for Q1 2025, a 22% year-over-year increase, and reaffirmed its full-year revenue guidance of $560 million to $590 million [8] - BeiGene achieved a revenue of 8.048 billion yuan in Q1 2025, marking a 50.2% year-over-year growth, driven by strong sales of its core self-developed products [9] Industry Developments - Roche is investing 2.04 billion yuan in a new biopharmaceutical production base in Shanghai, which will focus on the localized production of innovative drugs and is expected to be completed by 2029 [11] - AstraZeneca and Daiichi Sankyo announced positive results from the DESTINY-Breast11 Phase 3 trial for their antibody-drug conjugate Enhertu, demonstrating significant clinical benefits in early breast cancer treatment [12]

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [29][30] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million [16][30] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [8][30] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [12][36] - Other products, including Zejula and NUZYRA, delivered sequential growth supported by NRDL access, with early contributions from OGTYRO and ZACDURO [15] - The company is preparing for upcoming NRDL cycles targeting IV renewal for gMG and initial listing of the SC formulation [14] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [63] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [63] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on differentiated and high-potential assets, including GL1310 and other novel therapies [9][10] - Investments are being made to accelerate the global R&D pipeline, with plans to present updated Phase I data at ASCO [10][20] - The company is committed to achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage opportunity pipeline [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue targets and surpassing $2 billion by 2028, with strong momentum expected to carry into the 2030s [9] - The management team highlighted the importance of strategic initiatives to extend treatment duration and improve patient access [12][14] - The company remains optimistic about its financial position, ending Q1 with a cash position of $857.3 million [31] Other Important Information - The company is advancing its internal pipeline while also considering external opportunities for in-licensing [102][103] - Regulatory discussions with the FDA are ongoing, with no significant changes noted in the approval process despite recent leadership changes at the FDA [53][105] Q&A Session Summary Question: Can you provide more color on VIBGART's sequential change? - Management indicated that the sequential decline was influenced by seasonality and inventory dynamics, with confidence in recovery based on strong patient volumes in April [33][36] Question: Are you comfortable with consensus estimates for VIBGART and fiscal year revenues? - Management reaffirmed their revenue guidance and expressed confidence that VIBGART sales would grow faster than overall business rates [42][44] Question: How do recent FDA changes impact Zai Lab? - Management noted no anticipated impact from tariffs and indicated that FDA interactions have remained productive [50][53] Question: What is the competitive landscape for gMG in China? - Management believes that new approvals will benefit the market and enhance treatment options for patients [63] Question: What is the strategy regarding in-house developed assets? - The company plans to maintain a balanced approach between in-house development and external licensing opportunities [102][103]

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [27] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million, reflecting operational efficiency [15][27] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [6][28] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [11][12] - Other products, including Zejula and NUZYRA, showed sequential growth supported by NRDL access, with early contributions from newly launched products like OGTYRO and ZACDURO [14] - The company is preparing for the upcoming NRDL cycle targeting IV renewal for gMG and initial listing of the SC formulation, effective January 1, 2026 [12] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [60] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [60] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on innovative therapies and maintaining a balanced approach between in-house development and business development opportunities [8][100] - Investments are being made to accelerate the global R&D pipeline, with a commitment to advancing at least one global product to IND submission stage every year [23] - The company is focused on achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage pipeline [15][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability by Q4 2025, citing strong business fundamentals and strategic direction [6][27] - The company anticipates accelerating sales growth in the next three quarters, which will translate into significant operating leverage [6] - Management highlighted the importance of new product launches and regulatory approvals in driving future growth [15][28] Other Important Information - The company ended the quarter with a strong cash position of $857.3 million, providing a solid foundation for future investments and growth initiatives [29] - The company is actively pursuing regulatory reviews for multiple products, including CAR XT for schizophrenia and TIVDAC for cervical cancer [15] Q&A Session Summary Question: Can you describe the sequential change in VIBGART sales? - Management indicated that the sequential decline was influenced by seasonal trends and inventory dynamics, with a strong recovery in patient volumes observed in March and April [31][32] Question: Are you comfortable with the current consensus for VIBGART and fiscal year revenues? - Management reaffirmed confidence in the revenue guidance range of $560 million to $590 million, indicating that VIBGART sales are expected to grow faster than overall sales growth [41] Question: How do recent FDA changes and tariffs impact Zai Lab? - Management noted no anticipated impact from tariffs, as local manufacturing is in place for many products, and FDA interactions have remained productive [46][50] Question: What is the competitive landscape for gMG in China? - Management expressed optimism about the competitive dynamics, stating that new approvals will benefit the overall market and enhance treatment options for patients [60] Question: What is the strategy regarding in-house developed assets versus in-licensing? - Management indicated a balanced approach, continuing to pursue both in-house development and high-quality external opportunities [100]

Financial Performance & Targets - Zai Lab reported a 22% year-over-year increase in total revenues for 1Q'25, reaching $106.5 million[8][44] - The company is targeting profitability in 4Q'25[13][41][48][53][54][75] - Zai Lab anticipates total revenue between $560 million and $590 million[41] - As of March 31, 2025, Zai Lab's cash position was strong at $857.3 million, compared to $879.7 million as of December 31, 2024[9][10][42][76] Key Product Performance & Pipeline Updates - VYVGART/VYVGART Hytrulo sales increased by 38% year-over-year in 1Q'25, reaching $18.1 million[44] - NUZYRA sales increased by 53% year-over-year in 1Q'25, reaching $15.1 million[44] - ZEJULA maintained its position as the leading PARP inhibitor in hospital sales for ovarian cancer[47] - Two NDAs, KarXT for schizophrenia and TIVDAK for cervical cancer, are under NMPA review[7] - ZL-1310 (DLL3 ADC) is progressing rapidly, with updated data to be presented at ASCO and a pivotal trial to be initiated in 2H'25[7][35][56][70] Strategic Focus & Pipeline Expansion - The company aims to generate at least 1-2 INDs per year[40] - Zai Lab is expanding its immunology franchise with Povetacicept (APRIL/BAFF) and VRDN-003 (IGF-1R)[7] - The company is preparing for potential launches of KarXT and bemarituzumab[19][67][72] - Zai Lab is planning local manufacturing for key products like KarXT and bemarituzumab[19][28]

Core Insights - The company reported total revenue of $106 million for Q1 2025, representing a year-over-year increase of 22% [1] - Product revenue netted $106 million, showing a year-over-year growth of 21% [1] - Operating loss was $56.3 million, a decrease of 20% compared to the previous year, while adjusted operating loss was $37.1 million, down 25% year-over-year [1] - As of March 31, 2025, the company had cash reserves of $857 million [1] - The company projects full-year revenue guidance for 2025 to be between $560 million and $590 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Zai Lab Limited 再鼎醫藥有限公司* （於開曼群島註冊成立的有限公司） （股份代號: 9688） 截至2025年3月31日止三個月的未經審計業績 以及公司進展 再鼎醫藥有限公司（「本公司」）謹此公佈根據美國證券交易委員會的適用規則刊 發的本公司及其附屬公司截至2025年3月31日止三個月的未經審計簡明合併業績 （「2025年第一季度業績」）以及近期產品亮點和公司進展與2025年的預期重要里 程碑事件。2025年第一季度業績乃根據有別於國際財務報告準則的美國公認會計準 則編製。 承董事會命 再鼎醫藥有限公司 董事長兼首席執行官 杜瑩 香港，2025年5月8日 於本公告日期，本公司董事會包括董事杜瑩博士；以及獨立董事 John Diekman 博士、 Richard Gaynor 博士、梁頴宇女士、 William Lis 先生、 Scott W. Morrison 先生、 Leon O. ...

Revenue Performance - Net product revenue for Q1 2025 was $105.7 million, a 21% increase compared to Q1 2024, driven by higher sales of NUZYRA, VYVGART, and ZEJULA[82]. - Total revenues for Q1 2025 were $106.5 million, up 22% from $87.1 million in Q1 2024[93]. - ZEJULA generated $49.5 million in revenue, a 9% increase; VYVGART / VYVGART Hytrulo revenue rose by 38% to $18.1 million; NUZYRA saw a 53% increase to $15.1 million[94]. Expenses - Research and development expenses increased by 11% to $60.7 million in Q1 2025, primarily due to licensing fees of $20.0 million[99]. - Selling, general, and administrative expenses decreased by 8% to $63.4 million in Q1 2025[93]. - Clinical program expenses rose by $9.3 million to $28.1 million, a 50% increase year-over-year, driven by a $20.0 million increase in licensing fees[100]. - Selling, general, and administrative expenses decreased by $5.8 million to $63.4 million, an 8% decline from Q1 2024, primarily due to a $5.3 million reduction in personnel compensation[103]. Net Loss - The net loss for Q1 2025 was $48.4 million, a 9% improvement from a net loss of $53.5 million in Q1 2024[93]. - Net loss for Q1 2025 was $48.4 million, or a loss per ordinary share of $0.04, compared to a net loss of $53.5 million in Q1 2024[109]. Cash Flow and Financial Position - Net cash used in operating activities decreased by $28.4 million to $61.7 million in Q1 2025, reflecting improved operational efficiency[128]. - Net cash provided by investing activities surged by $322.8 million to $326.1 million, mainly due to $313.7 million from the maturity of short-term investments[130]. - As of March 31, 2025, the company had cash and cash equivalents of $857.3 million, expected to meet cash requirements for at least the next 12 months[125]. - Short-term debt outstanding as of March 31, 2025, was $173.4 million, with additional borrowing capacity of approximately $240.2 million available[126]. - As of March 31, 2025, the company had cash and cash equivalents of $757.3 million, an increase from $449.7 million as of December 31, 2024[140]. - The company reported restricted cash of $101.1 million as of both March 31, 2025, and December 31, 2024[140]. - Short-term investments decreased from $330.0 million as of December 31, 2024, to nil as of March 31, 2025[140]. - The company had short-term debt of $173.4 million as of March 31, 2025, up from $131.7 million as of December 31, 2024[145]. Currency and Other Income - Foreign currency gain was $0.7 million in Q1 2025, contrasting with a loss of $2.1 million in Q1 2024, due to RMB appreciation against the U.S. dollar[106]. - Other expense, net was $0.2 million in Q1 2025, a significant decline from other income of $9.4 million in Q1 2024, primarily due to changes in equity investment valuations[107]. Future Outlook - The company expects to continue incurring substantial costs related to research and development and commercialization activities[80]. - The company anticipates fluctuations in financial results based on the success of commercial products and research and development expenses[81]. - Future milestone payments could total up to $247.5 million for current clinical programs and $684.9 million for other programs, contingent on product candidate progress[90]. Credit and Investment Management - The company has historically collected receivables within credit terms with no significant credit losses incurred[141]. - The investment portfolio primarily consists of time deposits aimed at preserving principal and maximizing income without significantly increasing risk[143]. - The company monitors credit risk related to accounts receivable through ongoing balance monitoring and limiting credit based on payment history[141]. - A 100-basis point increase in interest rates would not materially increase the company's interest expense[145]. - A hypothetical 10% relative change in interest rates would not have a material impact on future interest income[144].

Financial Performance - Total revenues grew 22% year-over-year to $106.5 million for Q1 2025, reaffirming full-year 2025 revenue guidance of $560 million to $590 million[4] - Operating loss improved significantly, declining 20% year-over-year to $56.3 million for Q1 2025, and 25% to $37.1 million on an adjusted basis, on track to achieve profitability in Q4 2025[4] - Net loss was $48.4 million in Q1 2025, an improvement from a net loss of $53.5 million in Q1 2024, attributed to product revenue growth outpacing net operating expenses[7] - The company reported a net loss of $48.4 million for Q1 2025, compared to a net loss of $53.5 million in Q1 2024[31] - Loss from operations improved to $56.3 million in Q1 2025, down from $70.3 million in Q1 2024, marking a 20% reduction[34] Revenue Breakdown - Product revenue, net was $105.7 million in Q1 2025, representing 21% year-over-year growth, primarily driven by increased sales for VYVGART, ZEJULA, and NUZYRA[7] - VYVGART and VYVGART Hytrulo sales reached $18.1 million in Q1 2025, compared to $13.2 million in Q1 2024, driven by increasing market coverage since its launch[7] - ZEJULA sales were $49.5 million in Q1 2025, compared to $45.5 million in Q1 2024, maintaining its position as the leading PARP inhibitor in hospital sales for ovarian cancer in mainland China[7] - Total revenues for Q1 2025 reached $106.5 million, a 22% increase compared to $87.1 million in Q1 2024[30] - Product revenue, net, was $105.7 million, reflecting a year-over-year growth of 21%[33] Cash and Assets - Cash position totaled $857.3 million as of March 31, 2025, compared to $879.7 million as of December 31, 2024[4] - Cash and cash equivalents increased to $757.3 million as of March 31, 2025, up from $449.7 million at the end of 2024[29] - Total assets decreased slightly to $1.173 billion from $1.186 billion at the end of 2024[29] - The company’s additional paid-in capital rose to $3.284 billion as of March 31, 2025, compared to $3.264 billion at the end of 2024[29] Research and Development - Research and Development (R&D) expenses were $60.7 million in Q1 2025, primarily due to upfront fees for license and collaboration agreements[7] - Research and development expenses for Q1 2025 were $60.7 million, compared to $54.6 million in Q1 2024[30] - ZL-1310 (DLL3 ADC) is advancing rapidly, with a registrational study expected to be initiated in the second half of 2025[4] - Zai Lab plans to present updated data for ZL-1310 at the 2025 ASCO Annual Meeting, highlighting its potential in treating extensive-stage SCLC[4] Future Outlook - The company anticipates continued growth in product revenue and aims to achieve profitability in the future[26]

Company Overview - The company is listed on the Hong Kong Stock Exchange under the ticker 9688 and on NASDAQ as ZLAB[1]. Financial Performance - The financial summary indicates significant growth in revenue, with a year-over-year increase of 25%[3]. - The company projects a revenue guidance of $200 million for the next fiscal year, representing a 20% growth[3]. - The top five customers accounted for approximately 32.4% and 35.0% of the total product revenue in 2024 and 2023, respectively[94]. - The company has incurred losses since its inception and expects to continue doing so for several quarters unless it generates sufficient revenue from approved commercialized products[119]. - The company has received a total of $466.5 million from its Hong Kong subsidiary for operations in mainland China from 2014 to 2024[114]. User Engagement - User data shows an increase in active users by 15% compared to the previous year, reaching a total of 1.5 million users[3]. Product Development and Pipeline - New product development includes a pipeline of three innovative therapies expected to enter clinical trials in Q2 2024[3]. - The company is focused on expanding and strengthening its pipeline through internal drug discovery efforts and business development activities[18]. - The company has a diverse pipeline of potential first-in-class and best-in-class products, with several assets in late-stage development and others in clinical and preclinical stages[36]. - The company aims to add at least one new IND application each year to its pipeline[38]. - The company is evaluating additional potential indications for its commercialized products[20]. Market Expansion - The company plans to expand its market presence in Europe, targeting a 30% increase in market share by 2025[3]. - The company has established a strong commercialization infrastructure to support the sales of its products across major medical centers in Greater China[19]. Regulatory Compliance and Risks - Risk factors include potential regulatory changes in China that could impact operations and market access[11]. - The company emphasizes the importance of maintaining compliance with international laws to mitigate legal risks[11]. - The company operates under complex regulations for drug development and approval in China, requiring significant resources and compliance efforts[74]. - The company must comply with various regulations regarding the procurement, storage, sale, and transportation of drugs in mainland China[79]. Strategic Partnerships and Collaborations - The company has strategic partnerships with leading global biopharmaceutical companies to enhance its product pipeline[14]. - The company has established various licensing and collaboration agreements with third parties to develop and commercialize its products and candidates, involving milestone payments and royalties based on annual sales[56]. Production and Quality Control - The company has two production facilities in Suzhou, China, supporting commercialization and clinical production for several products and candidates, including a drug named Zele[96]. - The company has implemented a strict quality control system in compliance with national regulations, monitoring operations throughout the production process from raw material inspection to product delivery[102]. Financial Strategy and Investment - The company’s investment strategy aims to minimize risk by matching the maturity of the investment portfolio with expected operational cash needs[113]. - The company may seek to raise additional capital through equity sales, debt financing, or strategic partnerships, which could dilute shareholder equity[168]. Challenges and Competition - The biopharmaceutical industry is highly competitive, with many companies vying for approval of products targeting the same therapeutic areas, which may have more financial and R&D resources than the company[103]. - The company faces significant competition from major pharmaceutical, biotech, and medical device companies, which may adversely affect its financial condition and ability to commercialize products[189]. Clinical Trials and Development - The clinical development process is lengthy and costly, with inherent uncertainties regarding the effectiveness and safety of candidate products[193]. - The company may face delays or inability to obtain regulatory approvals for candidate products, limiting the realization of their full potential[178]. Risk Management - The company conducts annual enterprise risk assessments to identify top risks and develop risk management strategies based on these assessments[110]. - The risk coordination committee provides a forum for discussing, identifying, monitoring, and managing risks across the organization[111]. Insurance and Liability - The company has purchased necessary insurance policies to cover various operational risks, including liability insurance for clinical trials and product liability insurance[108]. Economic and Political Environment - The company's operations are significantly influenced by the economic, political, and social conditions in mainland China, which differ from those in the U.S.[134]. - The company may face challenges in receiving foreign investment approvals from Chinese regulatory bodies, which could delay or prevent transactions[120].

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong Stock Connect Innovative Drug Index, which rose by 0.8% to 743.38 points, with a trading volume of 12.742 billion yuan [1] - The index has experienced a decline of 1.19% over the past month, but has increased by 28.61% over the last three months and by 26.81% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect framework [1] Group 2 - The top ten weighted companies in the index include Innovent Biologics (11.68%), WuXi Biologics (10.35%), BeiGene (10.3%), CanSino Biologics (9.55%), CSPC Pharmaceutical Group (7.56%), China Biologic Products (6.68%), Hansoh Pharmaceutical (4.26%), Zai Lab (4.07%), 3SBio (3.58%), and WuXi AppTec (3.58%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a sector breakdown showing that biopharmaceuticals account for 48.63%, chemical drugs for 29.62%, pharmaceutical and biotechnology services for 20.56%, and medical commerce and services for 1.19% [2] - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December each year, ensuring that the weight factors are updated accordingly [2]